{"id":6009,"date":"2024-09-25T07:34:00","date_gmt":"2024-09-25T05:34:00","guid":{"rendered":"https:\/\/www.ehc.eu\/non-classifiee\/mise-a-jour-sur-la-deviation-de-fabrication-de-novo-nordisk-pour-novoseven-entrainant-des-penuries-pour-novoeight-et-esperoct\/"},"modified":"2026-04-02T16:31:01","modified_gmt":"2026-04-02T14:31:01","slug":"mise-a-jour-sur-la-deviation-de-fabrication-de-novo-nordisk-pour-novoseven-entrainant-des-penuries-pour-novoeight-et-esperoct","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/fr\/nouvelles\/mise-a-jour-sur-la-deviation-de-fabrication-de-novo-nordisk-pour-novoseven-entrainant-des-penuries-pour-novoeight-et-esperoct\/","title":{"rendered":"Mise \u00e0 jour sur la d\u00e9viation de fabrication de Novo Nordisk pour NovoSeven\u00a9, entra\u00eenant des p\u00e9nuries pour NovoEight\u00a9 et Esperoct\u00a9"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-7\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h3\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">Mise \u00e0 jour sur la d\u00e9viation de fabrication de Novo Nordisk pour NovoSeven\u00a9, entra\u00eenant des p\u00e9nuries pour NovoEight\u00a9 et Esperoct\u00a9<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p>Mi-juin 2024, le <strong>Consortium europ\u00e9en pour l\u2019h\u00e9mophilie (EHC),<\/strong> <a href=\"https:\/\/www.bleeding.org\/\" target=\"_blank\" rel=\"noopener\"><strong>la National Bleeding Disorder Foundation (NBDF)<\/strong><\/a> et <a href=\"https:\/\/wfh.org\/\" target=\"_blank\" rel=\"noopener\"><strong>la F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie (WFH)<\/strong><\/a> ont \u00e9t\u00e9 inform\u00e9s d\u2019une d\u00e9viation dans les cha\u00eenes de production de plusieurs produits destin\u00e9s au traitement de l\u2019h\u00e9mophilie et d\u2019autres coagulopathies fabriqu\u00e9s par Novo Nordisk au Danemark. Cette d\u00e9viation de fabrication a entra\u00een\u00e9 la sous-pourcharge potentielle de certains flacons de NovoSeven (1 et 2 mg) dans les pays inform\u00e9s et a entra\u00een\u00e9 des p\u00e9nuries de NovoSeven, NovoEight et Esperoct. <\/p>\n<p>Les probl\u00e8mes potentiels d\u2019approvisionnement de NovoEight (un concentr\u00e9 standard de FVIII \u00e0 demi-vie) et d\u2019Esperoct (un concentr\u00e9 de FVIII \u00e0 demi-vie prolong\u00e9e), bien que significatifs, peuvent \u00eatre att\u00e9nu\u00e9s gr\u00e2ce \u00e0 plusieurs concentr\u00e9s alternatifs de facteurs de coagulation standard standard et\/ou prolong\u00e9s. L\u2019EHC, le NBDF et le t\u00e9l\u00e9travail s\u2019attendent \u00e0 ce que Novo Nordisk fournisse des mises \u00e0 jour en temps opportun sur les p\u00e9nuries potentielles et le calendrier de retour \u00e0 la normale. <\/p>\n<p>Le probl\u00e8me manufacturier n\u2019a pas caus\u00e9 de graves probl\u00e8mes d\u2019approvisionnement pour l\u2019instant, mais son impact complet pourrait se manifester plus tard, probablement d\u2019ici la fin de 2024.<\/p>\n<p>L\u2019EHC et le WFH ont communiqu\u00e9 avec leurs organisations membres nationales (NMO) et continueront \u00e0 les informer de toute information pertinente fournie par Novo Nordisk. Les centres de traitement de l\u2019h\u00e9mophilie (HTC) et les r\u00e9gulateurs du monde entier sont au courant de la situation. <\/p>\n<p>L\u2019EHC, la NBDF et le t\u00e9l\u00e9travail sont rest\u00e9s en contact avec Novo Nordisk et attendent plus de d\u00e9tails sur les stocks en quarantaine, le nombre de fioles susceptibles d\u2019\u00eatre exp\u00e9di\u00e9s et utilis\u00e9s, ainsi que sur le calendrier pour revenir \u00e0 la normale pour les trois m\u00e9dicaments.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/ehc.eu\/wp-content\/uploads\/2024\/11\/2024-NN-Manufacturing-Issue-FINAL-Statement-V2.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the full statement<\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n<!-- related-posts -->","protected":false},"excerpt":{"rendered":"<p>Mi-juin 2024, l\u2019EHC, la NBDF et le t\u00e9l\u00e9travail ont \u00e9t\u00e9 inform\u00e9s d\u2019une d\u00e9viation dans les cha\u00eenes de production de plusieurs produits destin\u00e9s au traitement de l\u2019h\u00e9mophilie et d\u2019autres coagulopathies fabriqu\u00e9s par Novo Nordisk au Danemark.<\/p>\n","protected":false},"author":2,"featured_media":1171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[64,132],"tags":[145],"class_list":["post-6009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles","category-perspectives","tag-novo-nordisk"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2024\/10\/image-2.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/comments?post=6009"}],"version-history":[{"count":1,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6009\/revisions"}],"predecessor-version":[{"id":6019,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6009\/revisions\/6019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media\/1171"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media?parent=6009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/categories?post=6009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/tags?post=6009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}